Literature DB >> 12618292

Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease.

Thomas Müller1, Wilfried Kuhn, Thorsten Schulte, Horst Przuntek.   

Abstract

Intravenous application of amantadine sulphate induces a rapid improvement of motor symptoms in Parkinson's disease (PD), but there are no trials on the efficacy of this compound on bradykinesia, rigidity and tremor in detail in combination with standardized instrumental measurement of tapping and peg insertion abilities. We treated 31 stable non fluctuating PD patients with amantadine, scored motor symptoms of both arms and performed peg insertion and tapping under cued conditions before and after 3 days. Motor symptoms and peg insertion significantly improved in contrast to tapping. Tapping asks for repetitive performance of simple standardized movements, therefore it needs low cognitive efforts. Since peg insertion depends on more complex movements and thus more dopamine dependent cognitive processes, it improved after application of the indirect dopaminomimetic substance amantadine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618292     DOI: 10.1016/s0304-3940(02)01462-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial.

Authors:  Jee Young Lee; Sohee Oh; Jong Min Kim; Ji Sun Kim; Eungseok Oh; Hee-Tae Kim; Beom S Jeon; Jin Whan Cho
Journal:  J Neurol       Date:  2013-09-22       Impact factor: 4.849

2.  Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.

Authors:  Thomas Müller; Birgit Voss; Kerstin Hellwig; Franz Josef Stein; Thorsten Schulte; Horst Przuntek
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

Authors:  T Müller; L Ander; K Kolf; D Woitalla; S Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

4.  Drug therapy in patients with Parkinson's disease.

Authors:  Thomas Müller
Journal:  Transl Neurodegener       Date:  2012-05-24       Impact factor: 8.014

5.  Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson's Disease.

Authors:  Siegfried Muhlack; Patricia Müsch; Sandra Konietzka; Dirk Woitalla; Horst Przuntek; Thomas Müller
Journal:  Pharmaceutics       Date:  2010-09-20       Impact factor: 6.321

6.  Rivastigmine in the treatment of patients with Alzheimer's disease.

Authors:  Thomas Müller
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.